Get the Stockscreener App
19.92
0.41%
0.22
Seres Therapeutics Inc stock is traded at $19.92, with a volume of 43,225.
It is up +0.41% in the last 24 hours and up +26.08% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$19.70
Open:
$19.699
24h Volume:
43,225
Relative Volume:
0.27
Market Cap:
$174.22M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-996.00
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
+0.72%
1M Performance:
+26.08%
6M Performance:
+114.09%
1Y Performance:
+21.29%
1-Day Range:
$19.55
$20.85
1-Week Range:
$18.54
$20.85
52-Week Range:
$6.53
$24.67
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
19.90 | 172.47M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.12 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
480.15 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.60 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
818.45 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.88 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Is Seres Therapeutics Inc. stock a contrarian buyQuarterly Profit Review & Community Verified Swing Trade Signals - newser.com
Seres Therapeutics (MCRB) to Present New Phase 1b Trial Data at IDWeek 2025 - GuruFocus
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant - The Manila Times
Seres Therapeutics Presents 77% BSI Reduction in SER-155 Phase 1b | MCRB Stock News - Stock Titan
How Seres Therapeutics Inc. (1S90) stock moves on employment dataMarket Performance Recap & Stock Timing and Entry Methods - newser.com
News impact scoring models applied to Seres Therapeutics Inc.CPI Data & Fast Gaining Stock Strategy Reports - newser.com
Vontobel Holding Ltd. Has $892,000 Holdings in Seres Therapeutics, Inc. $MCRB - MarketBeat
Will Seres Therapeutics Inc. stock benefit from infrastructure spendingMarket Performance Report & High Accuracy Trade Alerts - newser.com
Is Seres Therapeutics Inc. stock supported by innovation pipelineMarket Movement Recap & Consistent Profit Trade Alerts - newser.com
Seres Therapeutics soars on report of takeover offer - MSN
Exit strategy if you’re trapped in Seres Therapeutics Inc.Weekly Trading Summary & Expert Verified Movement Alerts - newser.com
Is Seres Therapeutics Inc. forming a bottoming baseTreasury Yields & Long-Term Growth Plans - newser.com
Can you recover from losses in Seres Therapeutics Inc.Weekly Stock Recap & AI Powered Trade Plan Recommendations - newser.com
Quantitative breakdown of Seres Therapeutics Inc. recent moveCPI Data & Stepwise Swing Trade Plans - newser.com
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Is it too late to sell Seres Therapeutics Inc.2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
Seres Therapeutics (NASDAQ:MCRB) Receives "Sell (D+)" Rating from Weiss Ratings - MarketBeat
Building trade automation scripts for Seres Therapeutics Inc.July 2025 Macro Moves & High Return Trade Opportunity Guides - newser.com
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Target Price at $14.33 - Defense World
Technical signs of recovery in Seres Therapeutics Inc.July 2025 Trends & Verified Momentum Watchlists - newser.com
Seres Therapeutics Inc. stock retracement – recovery analysisMarket Rally & Free Risk Controlled Daily Trade Plans - newser.com
How high can Seres Therapeutics Inc. stock goMarket Activity Summary & Daily Momentum Trading Reports - newser.com
Published on: 2025-10-05 04:28:16 - newser.com
Understanding Seres Therapeutics Inc.’s price movementJuly 2025 PostEarnings & Pattern Based Trade Signal System - newser.com
Is Seres Therapeutics Inc. a candidate for recovery playJuly 2025 Update & Daily Entry Point Alerts - newser.com
Seres Therapeutics announces workforce reduction to extend cash runway - Investing.com
Seres Therapeutics Cuts Costs to Extend Cash Runway - TipRanks
Dated alerts on Seres Therapeutics' measures to cut costs withdrawn - MarketScreener
Developing predictive dashboards with Seres Therapeutics Inc. dataWeekly Earnings Recap & AI Enhanced Trading Signals - newser.com
Using data tools to time your Seres Therapeutics Inc. exit2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-10-03 00:05:20 - newser.com
Is Seres Therapeutics Inc a good long term investmentShort-Term Trading Alerts & Outperform the Market with Aggressive Picks - earlytimes.in
Goldman Sachs Group Inc. Acquires 21,679 Shares of Seres Therapeutics, Inc. $MCRB - MarketBeat
What analysts say about Seres Therapeutics Inc stockInstitutional Holding Changes & Capitalize On Fast Trends - earlytimes.in
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.77%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):